A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Tran, B.; Kouros-Mehr, H.; Fermin, A.; Horvath, L.; Roncolato, F.; Rettig, M.; Dorff, T.; Tagawa, S. T.; Subudhi, S. K.; Antonarakis, E. S.; Armstrong, A. J.; Petrylak, D. P.; Fizazi, K.; Salvati, M. E.; Scher, H. I. |
| Abstract Title: | A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz248.052 |
| Language: | English |
| ACCESSION: | WOS:000491295502322 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz248.052 |
| Notes: | Meeting Abstract: 895TiP -- Appears on page v353 of the abstract book -- Source: Wos |
